These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 26774385)
1. Phagocyte function decreases after high-dose treatment with melphalan and autologous stem cell transplantation in patients with multiple myeloma. Wichert S; Pettersson Å; Hellmark T; Johansson Å; Hansson M Exp Hematol; 2016 May; 44(5):342-351.e5. PubMed ID: 26774385 [TBL] [Abstract][Full Text] [Related]
2. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670 [TBL] [Abstract][Full Text] [Related]
3. The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy. Voorhees PM; Usmani SZ Clin Adv Hematol Oncol; 2016 Sep; 14(9):719-28. PubMed ID: 27673290 [TBL] [Abstract][Full Text] [Related]
4. Autologous stem-cell transplantation restores the functional properties of CD14+CD16+ monocytes in patients with myeloma and lymphoma. Dayyani F; Joeinig A; Ziegler-Heitbrock L; Schmidmaier R; Straka C; Emmerich B; Meinhardt G J Leukoc Biol; 2004 Feb; 75(2):207-13. PubMed ID: 14576364 [TBL] [Abstract][Full Text] [Related]
5. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312 [TBL] [Abstract][Full Text] [Related]
6. Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation. Lee SE; Lim JY; Kim TW; Ryu DB; Park SS; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min CK J Immunother Cancer; 2019 Feb; 7(1):35. PubMed ID: 30732646 [TBL] [Abstract][Full Text] [Related]
7. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation. Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157 [TBL] [Abstract][Full Text] [Related]
8. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. Mai EK; Benner A; Bertsch U; Brossart P; Hänel A; Kunzmann V; Naumann R; Neben K; Egerer G; Ho AD; Hillengass J; Raab MS; Neubauer A; Peyn A; Ko YD; Peter N; Scheid C; Goldschmidt H Br J Haematol; 2016 Jun; 173(5):731-41. PubMed ID: 26990892 [TBL] [Abstract][Full Text] [Related]
9. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study. Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830 [TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone. Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J; Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267 [TBL] [Abstract][Full Text] [Related]
11. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251 [TBL] [Abstract][Full Text] [Related]
12. Myeloma-Secreted Galectin-1 Potently Interacts with CD304 on Monocytic Myeloid-Derived Suppressor Cells. Lim JY; Kim TW; Ryu DB; Park SS; Lee SE; Kim BS; Min CK Cancer Immunol Res; 2021 May; 9(5):503-513. PubMed ID: 33771821 [TBL] [Abstract][Full Text] [Related]
14. Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case series. Nooka AK; Harvey RD; Langston A; Collins H; Lonial S; Kaufman JL Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):e59-63. PubMed ID: 24378319 [No Abstract] [Full Text] [Related]
15. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719 [TBL] [Abstract][Full Text] [Related]
16. High dose therapy followed by autologous peripheral blood stem cell transplantation as a first line treatment for multiple myeloma: a Korean Multicenter Study. Bang SM; Cho EK; Suh C; Yoon SS; Seong CM; Cho KS; Kang YG; Park S; Ahn MJ; Park YS; Oh D; Kim HC; Jung CW; Kim S; Lee JH J Korean Med Sci; 2003 Oct; 18(5):673-8. PubMed ID: 14555819 [TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents. Su B; Zhu X; Jiang Y; Wang L; Zhao N; Ran X; Zheng X; Guo H Leuk Lymphoma; 2019 Jun; 60(6):1381-1388. PubMed ID: 30516074 [TBL] [Abstract][Full Text] [Related]
18. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ; Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574 [TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells. Kayal S; Sharma A; Iqbal S; Tejomurtula T; Cyriac SL; Raina V Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):140-7. PubMed ID: 24342104 [TBL] [Abstract][Full Text] [Related]
20. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH; Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]